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a b s t r a c t
Background: The burden of influenza is increasingly recognised in Africa. The WHO recommends intro-
ducing influenza vaccination to high-risk groups: pregnant women, children <5 years, and the elderly.
The Gambia currently has no influenza vaccination policy, but the NASIMMUNE study, a clinical trial
of intranasal live attenuated influenza vaccines (LAIV) in young children provided an opportunity to
study maternal attitudes towards LAIV for the first time in sub-Saharan Africa. We assess acceptability
of LAIV, influenza knowledge and attitudes towards influenza vaccination in Gambian women.
Additionally, we investigate predictors of willingness to receive influenza vaccine (intent) in pregnancy
or seasonally for children <5.
Methods: A cross-sectional survey was conducted in Gambian women at two urban health facilities. To
assess LAIV acceptability, the exposure group (women whose children had received LAIV during the
NASIMMUNE study) were compared to a control group (women whose children were not enrolled in
the NASIMMUNE study). Demographics and health belief constructs were analysed as predictors of influ-
enza knowledge and vaccine intent.
Findings: The exposure group (n = 150) expressed a higher preference for a nasal spray vaccine than an
injection compared to the control group (n = 304) (93.3% vs. 34.9%, OR = 26.15, p < 0.0001). Those in
the exposure group who preferred the nasal spray found it less distressing, safer or equally safe, and
easier or equally easy to give (all p < 0.001) than injections. Influenza knowledge increased with educa-
tion level (p = 0.006 for higher education vs. none), and varied between sites (p = 0.0005). Vaccine intent
was >98%, but no association with influenza knowledge or difference between groups was observed.
Various health belief constructs were associated with vaccine intent.
Conclusion: LAIV acceptability was higher in those with first-hand experience. Influenza vaccine intent
was also high. Incorporation of seasonal LAIV into the childhood immunisation schedule in The
Gambia would be feasible, particularly if combined with community-based health education.
 2018 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Influenza is a major cause of acute respiratory infection glob-
ally, leading to a significant burden of morbidity and mortality
[1]. Seasonal influenza has been well-studied in high- and
middle-income countries, but neglected in Africa [2]. The rate of
influenza-associated hospitalisations in children <5 years of age
is approximately 3-fold higher in low- and middle-income coun-
tries (LMIC) compared to high-income countries [3]. One meta-
analysis found that 99% of deaths attributable to influenza-
associated acute lower respiratory infections occurred in LMICs [4].
As a result of the increasing awareness of influenza-related dis-
ease in LMIC, in 2012 the WHO recommended that countries
should consider influenza vaccination in high-risk groups includ-
ing pregnant women and children <5 years [5]. The Gambia has
no influenza vaccination policy and is yet to include influenza vac-
cination in the Expanded Programme on Immunisation (EPI) [6,7].
The NASIMMUNE study, a systems immunology research study in
children aged 24–59 months of intranasal live attenuated influenza
vaccine (LAIV) is ongoing (NCT02972957). To our knowledge, this
is the first interventional study in The Gambia using intranasal
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LAIV and offers a unique opportunity to study, for the first time,
attitudes towards a new mode of vaccine delivery in this setting.
Factors that shape parental views on vaccination impact child-
hood vaccination rates and having insight into parental percep-
tions can be useful when introducing new vaccinations to a
country [8]. High vaccine uptake in The Gambia through the EPI
[9] has led to reductions in invasive disease secondary to Hae-
mophilus influenzae type b [10] and Streptococcus pneumoniae
[11]. Yet as more vaccines are added to the EPI, vaccine hesitancy
might be a concern [12–14]. Knowledge and attitudes surrounding
influenza and influenza vaccination in The Gambia are unknown.
Gaining a better understanding of these factors can help guide
future influenza vaccination strategies, including maternal influ-
enza immunisation, shown to be beneficial to both mothers and
infants in recent studies from South Africa and Mali [15,16].
The Health Belief Model (HBM) provides a framework of psy-
chosocial constructs that may be determinants of health behaviour
[17]. It posits that preventative health behaviours are more likely
to be exhibited when an individual perceives they are highly sus-
ceptible to the disease, that the disease is serious, that the beha-
viour is beneficial, there are few barriers, and are cued into
action [18]. These constructs have been shown to predict uptake
of influenza vaccination and other health behaviours [19–24].
However, emotions experienced at the point of decision-making
may be as important in health behaviour as a cognitive assessment
of the risk, such as worry and anticipated regret, which have also
been shown to be predictive of influenza vaccination [20,25,26].
Few studies have used the HBM to study influenza vaccine beha-
viour in LMICs [27–31].
We aimed to compare attitudes towards the safety, ease of use,
and tolerability of LAIV between mothers with direct experience of
their children receiving LAIV and mothers without such experi-
ence, and to establish whether their attitudes towards intranasal
vaccines differ. Additionally, we aimed to quantify knowledge
about influenza and to determine possible relationships between
influenza knowledge, socio-demographic factors and willingness
to accept influenza vaccination in pregnancy or for their children
<5 (vaccine intent). Finally, we aimed to explore the relationship
between health belief constructs and influenza vaccine intent in
this cohort.
2. Methods
2.1. Study design
A cross-sectional survey was conducted in women 18 years at
two sites (Sukuta and Faji Kunda health centres) five kilometres
apart, in the coastal region of The Gambia in August and September
2017. In Sukuta, where NASIMMUNE was conducted, mothers of
children who had been vaccinated with the intranasal LAIV
(Nasovac-S, Serum Institute of India Pvt. Ltd.) as part of the study
were contacted sequentially and invited to an interview, up to a
total of 150 (exposure group). A further 154 women from Sukuta
who had not participated in the NASIMMUNE study were recruited
at the same health centre. Due to wider community sensitization
regarding the NASIMMUNE trial carried out in Sukuta, this group
may have had some exposure to information about influenza and
LAIV, therefore an additional control group of 150 women were
recruited at Faji Kunda health centre (where there could have been
no exposure to the study or community sensitization). These
women were recruited through opportunistic sampling when
attending for routine healthcare. The sample size was determined
by the availability of mothers of children in the NASIMMUNE study
(n = 168), with a 1:2 exposure to control ratio. Inclusion criteria
were having at least one child <5, maternal age 18, resident in
the area, and fluency in Mandinka (the most commonly spoken
local language in the areas).
2.2. Data collection
Face-to-face interviews were conducted by trained field-
workers who entered data in real-time into a questionnaire
designed in REDCapTM [32]. The questionnaire was developed using
simple terminology and was refined through cognitive pre-testing
with field-workers and test participants. The questionnaire
included seven sections: inclusion criteria, socio-demographics,
vaccine intent, influenza knowledge, health-seeking behaviour,
health beliefs, and LAIV acceptability. The influenza knowledge
questions were designed de novo for this setting, selected and sim-
plified from influenza knowledge questions used previously
[31,33–35] and refined following the cognitive pre-testing phase.
Questions asked about symptoms, transmission, prevention, treat-
ment, risk, and vaccination (see supplementary material: Appendix
A). The responses were collated to form a score out of 15 points,
which was converted to a percentage for analysis (score divided
by 15, multiplied by 100).
Influenza vaccine intent was assessed for pregnancy and for
children <5 by asking participants to respond to two statements:
‘‘If I was pregnant, I would get a flu vaccine if it was free” and ‘‘I
would get a flu vaccine for my child under 5, every year, if it was
free”. Answers were recorded on a 4-point scale where 1 = agree
strongly, 2 = agree, 3 = disagree and 4 = disagree strongly, with a
‘‘don’t know” option. In follow-up questions, unprompted reasons
given for answers were coded into predefined categories by the
interviewer.
Health belief constructs were assessed using statements
answered on the same 4-point scale. HBM constructs assessed
were: perceived susceptibility, severity, benefit, barriers and cues
to action. Two additional concepts were also included: worry and
anticipated regret. The answers given were converted into binary
‘‘agree” or ‘‘disagree” responses for analysis.
2.3. Ethical considerations
Ethical approval for the study was provided by The Gambia
Government/MRC Joint Ethics Committee (SCC1555). Written
informed consent was obtained from all participants. It was made
clear that answers were confidential and anonymised, that they
could withdraw at any time or decline to answer any questions.
2.4. Statistical analysis
Analysis was conducted using Stata 12.0. Descriptive statistics
were used to compare proportions between groups: Pearson’s chi-
squared test or two-tailed Fisher’s exact test (when one category
had <5 participants) for categorical data; and Student’s t-test or
Wilcoxon rank-sum test for normally and non-normally dis-
tributed continuous data respectively. Univariate linear regression
analysis was performed for predictors of influenza knowledge.
Significance-testing was used for selection of variables to include
in the multivariate model at a level of p < 0.2 to minimize type II
error in selection [36]. The Cochran–Mantel–Haenszel test was
used to analyse variations between groups for individual influenza
knowledge question responses and to evaluate the difference in
preference for intranasal or injection vaccinations between groups.
Two-tailed Fisher’s exact test was used to analyse perceptions of
intranasal LAIV in the exposed group and associations between
vaccine intent and health belief constructs. p < 0.05 was consid-
ered statistically significant.
E.P. Armitage et al. / Vaccine 36 (2018) 1772–1780 1773
3. Results
3.1. Participants’ characteristics
The 454 participants’ characteristics who answered the survey
are displayed in Table 1. There were significant differences between
the exposure and control groups with respect to age, parity, educa-
tion, husband’s education and monthly household income.
3.2. LAIV acceptability
When asked ‘‘If given a choice for your child between a flu vac-
cine injection and a nasal spray, which would you prefer?” a signif-
icantly higher proportion of the exposure group stated they would
prefer a nasal spray compared to the control group (93.3% vs.
34.9%, OR = 26.15, p < 0.0001, Table 2). The most common
unprompted reasons for preferring the nasal spray were that it is
easier to give, less painful and a perception of greater effectiveness
(Fig. 1A). The most commonly stated reasons for preferring injec-
tions were a greater familiarity with injections and a belief that
injections are more effective (Fig. 1B). In the exposure group, stat-
ing a preference for the nasal spray was associated with finding the
LAIV less distressing (p < 0.001), safer or equally safe (p < 0.001)
and easier or equally easy to give (p < 0.001) when compared to
injections (Table 2).
Table 1
Socio-demographic and other characteristics of participants by group.
Participant characteristics All n = 454 n (%) NASIMMUNE (exposure) n = 150 n (%) Non-NASIMMUNE (control) n = 304 n (%) P value
Interview site:
Sukuta 304 (67.0) 150 (100.0) 154 (50.7) –
Faji Kunda 150 (33.0) 0 (0.0) 150 (49.3) –
Mean% influenza knowledge score (SD) 68.0 (10.3) 69.2 (10.0) 67.4 (10.4) 0.0816*
Vaccine intent in pregnancy 447 (98.5) 150 (100.0) 297 (97.7) 0.185y
Vaccine intent for children < 5 years 448 (98.7) 146 (97.3) 302 (99.3) 0.600y
Socio-demographics:
Mean age (SD) 28.4 (5.6) 29.5 (5.1) 27.9 (5.7) 0.0026*
Median parity (IQR) 3 (2–5) 3 (2–5) 3 (2–5) 0.0340**
Median household size (IQR) 4 (3–6) 4 (3–5) 4 (3–6) 0.0852**
Currently pregnant 36 (7.9) 15 (10.0) 21 (6.9) 0.251
Another pregnancy in household 111 (24.5) 33 (22.0) 78 (25.7) 0.394
Marital status:
Never married 5 (1.1) 1 (0.7) 4 (1.3) –
First (and only) wife 344 (75.8) 118 (78.7) 226 (74.3) –
First (not only) wife 37 (8.2) 9 (6.0) 28 (9.2) –
Second wife 58 (12.8) 18 (12.0) 40 (13.2) –
Third or fourth wife 10 (2.2) 4 (2.7) 6 (2.0) 0.734y
Education (English school):
None 98 (21.6) 27 (18.0) 71 (23.4) –
Arabic school only 78 (17.2) 17 (11.3) 61 (20.1) –
Attended primary school 50 (11.0) 17 (11.3) 33 (10.9) –
Attended upper school 215 (47.4) 86 (57.3) 129 (42.4) –
Higher education 13 (2.9) 3 (2.0) 10 (3.3) 0.025y
Occupation:
None/house wife 266 (58.6) 79 (52.7) 187 (61.5) –
Student 3 (0.7) 1 (0.7) 2 (0.7) –
Self-employed (unskilled) 69 (15.2) 32 (21.3) 37 (12.2) –
Self-employed (skilled) 65 (14.3) 23 (15.3) 42 (13.8) –
Employed (salaried) 51 (11.2) 15 (10.0) 36 (11.8) 0.105y
Husband’s education:
None 42 (9.3) 6 (4.0) 36 (11.8) –
Arabic school only 61 (13.4) 13 (8.7) 48 (15.8) –
Attended primary school 16 (3.5) 7 (4.7) 9 (3.0) –
Attended upper school 259 (57.1) 89 (59.3) 170 (55.9) –
Higher education 51 (11.2) 23 (15.3) 28 (9.2) –
Don’t know 25 (5.5) 12 (8.0) 13 (4.3) 0.004
Husband’s occupation:
None 15 (3.3) 5 (3.3) 10 (3.3) –
Student 3 (0.7) 1 (0.7) 2 (0.7) –
Self-employed (unskilled) 6 (1.3) 2 (1.3) 4 (1.3) –
Self-employed (skilled) 161 (35.5) 48 (32.0) 113 (37.2) –
Employed (salaried) 253 (55.7) 93 (62.0) 160 (52.6) –
Don’t know 16 (3.5) 1 (0.7) 15 (4.9) 0.120y
Household income (GMD per month):
GMD 500-GMD 4,999 71 (15.6) 20 (13.3) 51 (16.8) –
GMD 5,000-GMD 9,999 186 (41.0) 70 (46.7) 116 (38.2) –
GMD >10,000 100 (22.0) 44 (29.3) 56 (18.4) –
Don’t know/unwilling to say 97 (21.4) 16 (10.7) 81 (26.6) <0.001
Monthly household income stated in Gambian Dalasis (GMD). 1 USD = 48 GMD at time of writing.
* Two-group mean-comparison t-test (normally distributed).
** Wilcoxon rank-sum test (non-normally distributed).
y Two-tailed Fisher’s exact test (when n < 5 in some cases).
 Pearson’s chi-squared test.
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3.3. Influenza knowledge
The mean percentage influenza knowledge score was 68.0% and
was not significantly different between exposure and control
groups (69.2% vs. 67.4%, p = 0.0816), although differences were
seen in individual questions (Fig. 2). Participants recruited at Faji
Kunda had significantly higher scores than at Sukuta (70.4% vs.
66.8%, p = 0.0005). When comparing exposure and control partici-
pants from Sukuta, the knowledge was significantly higher in the
exposure group (69.2% vs. 64.4%, p = 0.0001). Of the control partic-
ipants from Sukuta, only two (1.3%) had been asked to participate
in NASIMMUNE but did not.
The responses to individual knowledge questions are shown in
Fig. 2. A significantly higher proportion of exposure participants
could name all three core symptoms of influenza (11.3% vs. 3.0%,
OR = 4.19, p = 0.001), while a significantly lower proportion of
exposure group participants correctly identified that there is no
cure for influenza (11.3% vs. 23.0%, OR = 0.43, p = 0.004) but
thought ‘‘medication” could cure influenza (86.7% vs. 71.1%, OR =
2.65, p < 0.0001). There were no significant differences between
groups in any other questions.
Results of the univariate and multivariate linear regression
analysis of factors that predict influenza knowledge are presented
in Table 3. In the multivariate linear regression model, there was a
significantly higher level of influenza knowledge in participants
who had attended Arabic school, upper school or had higher edu-
cation compared to no education, exhibiting an increased score
with each stepwise increase in educational level. Additionally, par-
ticipants whose husbands were students showed a significantly
higher knowledge score than those whose husbands had no occu-
pation (b = 13.31, p = 0.032). The multivariate model explained a
significant proportion of the variance in influenza knowledge
(adjusted R2 = 0.1165, p < 0.0001).
3.4. Influenza vaccination intent
Almost all respondents stated that they agreed or agreed
strongly with the vaccine intent statements (98.5% and 98.7% for
pregnancy and children <5 respectively) and there was no differ-
ence in vaccine intent between groups (Table 1). Unprompted rea-
sons given for intent are shown in Fig. 1C. There was no association
between influenza knowledge and vaccine intent for pregnancy or
children <5 as shown in Table 3 (p = 0.782 and p = 0.817
respectively).
The associations between health belief concepts and vaccine
intent are presented in Table 4. For children <5, significant
Table 2
Intranasal LAIV preference and acceptability.
Question Levels NASIMMUNE (exposure) n = 150 n (%) Non-NASIMMUNE (control)
n = 304 n (%)
Cochran–Mantel–Haenszel odds
ratio (95% CI, p value)
Vaccine delivery preference Injection 10 (6.7) 198 (65.1) ref
Nasal spray 140 (93.3) 106 (34.9) 26.15 (11.51, 59.41, p < 0.0001)*
Levels Preferred injections
n = 10
Preferred nasal
spray n = 140
Two-tailed Fisher’s exact test
p value
Less distressing No 7 (70.0) 3 (2.1) – ref
Yes 3 (30.0) 137 (97.9) – <0.001*
Safer or equally safe No 8 (80.0) 2 (1.4) – ref
Yes 2 (20.0) 138 (98.6) – <0.001*
Easier or equally easy to give No 8 (80.0) 1 (0.7) – ref
Yes 2 (20.0) 139 (99.3) – <0.001*
* Significant p < 0.05. ref = reference category used for baseline comparison.
Fig. 1. Respondents’ unprompted reasons for answers given. (A) Respondents’ unprompted reasons for preferring nasal spray by group (exposure n = 140, control n = 106). (B)
Respondents’ unprompted reasons for preferring injections by group (exposure n = 10, control n = 198). (C) Respondents’ unprompted reasons for accepting an influenza
vaccine during pregnancy or for their children < 5 years (pregnant n = 447, children < 5 n = 448).
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associations were seen for perceived susceptibility, severity, bene-
fit, and barriers, while for pregnancy, only perceived susceptibility,
severity and worry were significantly associated with vaccine
intent.
4. Discussion
There are few countries with seasonal influenza vaccination in
sub-Saharan Africa, with none currently using intranasal LAIV
[37]. The NASIMMUNE study, ongoing in The Gambia, provided
an opportunity to study perceptions of intranasal LAIV between
mothers whose children had recently received LAIV and women
with no experience of LAIV. In the latter group, preference for an
intranasal vaccine was moderate at 34.9%, with the most com-
monly stated reasons for preferring an injection relating to famil-
iarity with injections and beliefs of greater effectiveness. Our
results show that in those with direct experience of LAIV, the pref-
erence for nasal spray was significantly higher, in keeping with
studies in high income countries [38,39]. Women in the exposure
group stated, unprompted, that nasal sprays were easier to give
than injections and that they were less painful, suggesting that
the LAIV given in NASIMMUNE was viewed favourably. These
results indicate that a future influenza vaccination programme in
The Gambia using intranasal LAIV in children <5 would be received
positively, particularly if the introduction were coupled with
demonstrations or educational sessions to promote their safety,
ease of use and effectiveness.
The influenza knowledge questions covered a range of
influenza-related topics including symptoms, transmission, sever-
ity, high-risk groups, treatment and vaccination. The educational
level in The Gambia is generally low, with many women illiterate,
and never attending school (21.6%). The mean knowledge scores
were no different between the exposure and control groups, but
a good understanding of disease and health-risk concepts was seen
overall despite the low formal education level.
Due to community sensitization and possible knowledge trans-
fer between NASIMMUNE study participants and non-study partic-
ipants in Sukuta, a control group from Faji Kunda who had had no
exposure to any trial information about influenza were included.
Surprisingly, Faji Kunda had significantly higher knowledge than
Sukuta overall. The effect was independent of education, which
was broadly similar between sites, although knowledge did
increase significantly with more education at both sites. The reason
for the higher scores in Faji Kunda is unclear, but health beliefs
within in the two communities may differ significantly and previ-
ous studies conducted at Faji Kunda may have influenced the
results. Several large vaccine trials have recently recruited children
through the Faji Kunda EPI clinic, which have included health,
hygiene and nutritional education as part of community sensitiza-
tion. One study from The Gambia has shown that such activities
effectively disseminate information throughout the community
[40], while others have shown that community social networks
are important to knowledge, particularly when access to external
information is limited [41]. Furthermore, educational women’s
groups can significantly improve health outcomes in low-income
settings [42,43]. Community health beliefs may, therefore, be as
important as formal education in regard to influenza-related
knowledge.
When comparing groups from Sukuta alone, influenza knowl-
edge was significantly higher in the exposure group, suggesting
that participation in the NASIMMUNE study may have increased
knowledge about influenza and vaccination. However, when asked
what can cure influenza, a significantly higher proportion of the
exposure group incorrectly answered ‘‘medication”, rather than
‘‘nothing/no treatment”. This could indicate that involvement in
the study led people to erroneously believe that specific anti-
influenza medications are available. Children presenting with
cough, fever and rhinorrhoea in the follow-up period of the NASIM-
MUNE study were commonly given paracetamol, which may have
been mistakenly regarded as a ‘‘cure”, possibly explaining the find-
ing. This is a reminder that clinical trials can inadvertently spread
misinformation in these settings and that steps should be taken to
mitigate this risk through careful provision of information during
informed consent processes and throughout studies [44–47].
Influenza vaccine intent was assessed by asking participants if
they would accept an influenza vaccine if it was freely available
for themselves during pregnancy or for their children <5. Over
98% of participants responded that they would accept the vaccina-
tion. The high intent could be explained by the clinical trials that
have been conducted at both health centres for many years, which
may have led to a high level of trust in healthcare in these commu-
nities. To avoid response bias, participants were reassured during
the interview that they should not feel pressured to answer in
the affirmative. Nonetheless, the high influenza vaccine intent
observed may be, in part, due to acquiescence bias or social
Fig. 2. Individual influenza knowledge question responses by group. Cochran–Mantel–Haenszel odds ratios and p values shown only for questions where groups differed
significantly. *Correct statements.
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Table 3
Predictors of influenza knowledge.
Predictors Linear regression
Total n = 453 (n = 1 excluded due to
missing data in knowledge questions)
Influenza knowledge
score
Univariate analysis Multivariate analysisy
Continuous/discrete mean % b 95% CI p value b 95% CI p value
Age (in years) – 0.02 0.15, 0.19 0.788 – – –
Parity – 0.67 1.13, 0.19 0.006* 0.16 0.66, 0.35 0.546
Number of people living in household – 0.25 0.66, 0.16 0.236 – – –
Categorical Levels
Group and site Sukuta (exposure) 69.2 ref – – ref – –
Sukuta (control) 64.4 4.71 6.96, 2.46 <0.001* 4.36 6.65, 2.07 <0.001**
Faji Kunda (control) 70.4 1.20 1.06, 3.46 0.298 1.49 0.90, 3.88 0.220
Marital status Never married 68.0 ref – – – – –
First and only wife 68.0 0.01 9.13, 9.11 0.998 – – –
First wife (not only) 67.9 0.07 9.72, 9.57 0.988 – – –
Second wife 67.2 0.76 10.19, 8.68 0.875 – – –
Third or fourth wife 71.3 3.33 7.76, 14.42 0.555 – – –
Educational level None 63.5 ref – – ref – –
Arabic school only 67.4 3.88 0.93, 6.83 0.010* 4.32 1.23, 7.42 0.006**
Attended primary school 67.3 3.88 0.48, 7.28 0.026* 3.40 0.03, 6.83 0.052
Attended upper school 69.8 6.36 3.99, 8.73 <0.001* 6.08 3.49, 8.68 <0.001**
Higher education 76.9 13.45 7.71, 19.19 <0.001* 9.71 2.84, 16.59 0.006**
Occupation None 67.9 ref – – ref – –
Student 80.0 12.13 0.46, 23.79 0.042* 5.40 6.53, 17.32 0.374
Self-employed (unskilled) 66.8 1.11 3.83, 1.60 0.422 1.06 3.76, 1.64 0.443
Self-employed (skilled trade) 67.2 0.69 3.48, 2.09 0.624 0.04 2.69, 2.77 0.977
Employed (salaried) 70.3 2.45 0.62, 5.52 0.117* 0.05 3.25, 3.35 0.977
Husband’s educational level None 67.1 ref – – ref – –
Arabic school only 65.9 1.24 5.27, 2.78 0.545 2.62 6.59, 1.35 0.195
Attended primary school 66.2 0.89 6.79, 5.00 0.766 0.37 6.02, 5.28 0.898
Attended upper school 68.2 1.05 2.29, 4.39 0.538 0.65 3.98, 2.69 0.704
Higher education 71.4 4.23 0.05, 8.41 0.048* 0.61 3.73, 4.95 0.783
Don’t know 66.1 1.01 6.08, 4.06 0.696 3.23 8.44, 1.98 0.223
Husband’s occupation None 65.8 ref – – ref – –
Student 77.8 12.00 0.78, 24.78 0.066* 13.31 1.17, 25.46 0.032**
Self-employed (unskilled) 70.0 4.22 5.54, 13.99 0.396 5.19 4.32, 14.70 0.284
Self-employed (skilled trade) 67.7 1.88 3.57, 7.34 0.498 3.83 1.39, 9.05 0.150
Employed (salaried) 68.1 2.29 3.08, 7.66 0.403 3.23 1.92, 8.37 0.218
Don’t knowy 68.9 3.11 4.27, 10.49 0.408 5.31 2.08, 12.70 0.159
Household income ( GMD per month) GMD 500-GMD 4,999 66.5 ref – – ref – –
GMD 5,000-GMD 9,999 68.2 1.59 1.23, 4.40 0.269 1.09 1.64, 3.82 0.432
GMD >10,000 69.2 2.68 0.46, 5.82 0.094* 1.72 1.36, 4.79 0.272
Don’t know/unwilling to say 67.6 1.15 2.00, 4.30 0.474 1.10 1.98, 4.18 0.481
Vaccination intent Levels
‘‘I would get a flu vaccine in pregnancy if
available for free”
Disagree 66.7 ref – – – – –
Agree 67.9 1.28 7.80, 10.36 0.782 – – –
‘‘I would get a flu vaccine for my child
under 5, every year, if it was free”
Disagree 66.7 ref – – – – –
Agree 68.0 1.37 10.27, 13.00 0.817 – – –
y Predictors included in the multivariate linear regression model (p values < 0.2): parity, group/site, educational level, occupation, husband’s educational level, husband’s occupation and monthly household income.
 Adjusted values.
* p < 0.2.
** Significant p < 0.05. ref = reference category used for baseline comparison.
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desirability bias. However, the unprompted stated reasons for their
answers confirmed that there is a strong belief that vaccines are
safe and effective, and related to vaccines generally rather than
influenza vaccines specifically. The high intent is also consistent
with the high EPI coverage in The Gambia (95% for BCG and 81–
99% for three Diphtheria-Pertussis-Tetanus doses) which is among
the highest in Africa [9]. Neither higher influenza knowledge nor
higher educational level were associated with vaccine intent. This
may be due to the small numbers disagreeing with the intent state-
ments, which also meant that the associations between health
belief constructs and vaccine intent could not be quantified, but
our results confirm previous findings elsewhere [19,20]. A larger
sample size would be required to determine which health belief
constructs are most predictive of vaccine intent in this setting.
A key limitation to this study is that opportunistic sampling was
used. The sample may therefore not be representative of the wider
community, which could explain the small observed differences in
socio-demographic makeup between groups. The higher educa-
tional level and income observed in the exposure group may be
due to more educated and affluent people being more willing
to participate in clinical trials. Future studies should use probabil-
ity sampling at more sites to better represent the knowledge,
attitudes and perceptions towards influenza and vaccination in
the country.
Table 4
Health belief constructs as predictors of vaccine intent.
Health belief construct Question wording Levels Vaccine intenty Two-tailed Fisher’s
exact p value
Disagree n (%) Agree n (%)
Children < 5
Perceived susceptibility ‘‘If my child under 5 had not been given the flu
vaccine, I would expect them to get flu”
Disagree 4 (100.0) 30 (6.7) <0.001*
Agree 0 (0.0) 415 (93.3)
Perceived severity ‘‘If my child under 5 caught flu, it would be more
mild than in the general public”
Disagree 2 (50.0) 188 (42.4) 1.000
Agree 2 (50.0) 257 (57.8)
‘‘If my child under 5 caught flu, they might need to
be admitted to hospital”
Disagree 1 (25.0) 4 (0.9) 0.044*
Agree 3 (75.0) 441 (99.1)
Perceived benefit ‘‘If my child under 5 was given the flu vaccine, it
would prevent them catching flu”
Disagree 3 (75.0) 3 (0.7) <0.001*
Agree 1 (25.0) 441 (99.3)
Perceived barriers ‘‘If my child under 5 had been given the flu vaccine,
the vaccine could give them flu”
Disagree 2 (50.0) 404 (91.0) 0.046*
Agree 2 (50.0) 40 (9.0)
‘‘The flu vaccine is unsafe for children” Disagree 2 (50.0) 406 (92.1) 0.036*
Agree 2 (50.0) 35 (7.9)
Cues to action ‘‘If a nurse or doctor recommended the flu vaccine
during pregnancy or for my child under 5, I would
agree to get it because of what they said”
Disagree 1 (25.0) 202 (45.1) 0.631
Agree 3 (75.0) 246 (54.9)
‘‘If my friends or relatives recommended the flu
vaccine during pregnancy or for my child under 5, I
would get it because of what they said”
Disagree 3 (100.0) 336 (75.3) 1.000
Agree 0 (0.0) 110 (24.7)
Worry ‘‘If my child under 5 hadn’t been given the flu
vaccine, I would worry about them getting flu”
Disagree 1 (25.0) 13 (2.9) 0.119
Agree 3 (75.0) 434 (97.1)
Anticipated regret ‘‘If I refused to get the flu vaccine for my child under
5, but then they got sick with flu, I would be angry
with myself”
Disagree 1 (25.0) 14 (3.1) 0.127
Agree 3 (75.0) 433 (96.9)
Pregnancy
Perceived susceptibility ‘‘If I was pregnant but hadn’t been given the flu
vaccine, I would expect to get flu”
Disagree 3 (50.0) 30 (6.9) 0.006*
Agree 3 (50.0) 407 (93.1)
Perceived severity ‘‘If I was pregnant and caught flu, it would be more
mild than in the general public”
Disagree 0 (0.0) 200 (45.1) 0.036*
Agree 6 (100.0) 244 (55.0)
Perceived benefit ‘‘If I had been given a flu vaccine during pregnancy,
it would prevent me catching flu”
Disagree 0 (0.0) 5 (1.1) 1.000
Agree 6 (100.0) 440 (98.9)
‘‘If I got a flu vaccine during pregnancy, it would
protect my baby from getting flu in the first few
months of life”
Disagree 0 (0.0) 5 (1.13) 1.000
Agree 6 (100.0) 439 (98.9)
Perceived barriers ‘‘The flu vaccine is unsafe during pregnancy” Disagree 4 (66.7) 402 (91.6) 0.090
Agree 2 (33.3) 37 (8.4)
‘‘If I got a flu vaccine during pregnancy, the vaccine
could give me flu”
Disagree 5 (83.3) 414 (93.7) 0.332
Agree 1 (16.7) 28 (6.3)
Cues to action ‘‘If a nurse or doctor recommended the flu vaccine
during pregnancy or for my child under 5, I would
agree to get it because of what they said”
Disagree 1 (16.7) 203 (45.4) 0.230
Agree 5 (83.3) 244 (54.6)
‘‘If my friends or relatives recommended the flu
vaccine during pregnancy or for my child under 5, I
would get it because of what they said”
Disagree 4 (66.7) 337 (75.9) 0.635
Agree 2 (33.3) 107 (24.1)
Worry ‘‘If I was pregnant and hadn’t been given the flu
vaccine, I would worry about getting flu”
Disagree 3 (50.0) 18 (4.0) 0.002*
Agree 3 (50.0) 429 (96.0)
Anticipated regret ‘‘If I was pregnant and refused to get the flu vaccine,
but then got sick with flu, I would be angry with
myself”
Disagree 1 (16.7) 24 (5.4) 0.290
Agree 5 (83.3) 423 (94.6)
y Participants who answered ‘‘don’t know” to health belief construct or vaccine intent questions omitted.
* Significant p < 0.05.
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Due to the high vaccine intent seen, the study was also under-
powered to explore associations between intent and knowledge, so
these should be interpreted cautiously. The intent questions spec-
ified that the vaccine was offered for free, so vaccine intent if the
vaccine was only available for a fee remains unknown. Addition-
ally, prior to being asked about LAIV preference over injections,
they were not informed about the effectiveness of each vaccine,
which may have altered their answers. Future studies could
address these limitations in similar surveys, or use qualitative
research methods to explore these attitudes in more depth, to gain
an understanding of the underlying beliefs and motivations behind
vaccine behaviour in The Gambia.
5. Conclusion
Willingness to undertake influenza vaccination during preg-
nancy, or to get annual seasonal vaccination for children <5 years
if freely available was high, as was acceptability of LAIV in those
with first-hand experience. Incorporation of the intranasal influ-
enza vaccine into the childhood immunisation schedule in The
Gambia in the future would likely be feasible from an acceptability
perspective. Knowledge and understanding of health-related con-
cepts surrounding influenza was generally good, though varied
between communities, and was significantly related to higher edu-
cational levels. Despite reasonable health knowledge in this low-
income, low-education setting, more formal education would have
a positive impact on influenza and health knowledge, and poten-
tially have wider community benefits as well. Community-based
educational interventions may also be beneficial in The Gambia.
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